8-K
filed February 28, 2024, 6:59 PM ET
ticker IART
CIK 0000917520
earnings
confidence high
sentiment neutral
materiality 0.75
Integra LifeSciences Q4 GAAP EPS $0.25 vs $0.63; guides FY2024 revenue up 4-5% organic
INTEGRA LIFESCIENCES HOLDINGS CORP
2023-FY EPS reported
$0.84
revenue$1,541,573,000
- Q4 revenues $397.0M, down 0.2% reported; organic revenue ex-Boston up 3.6%.
- GAAP EPS $0.25, adjusted EPS $0.89 vs $0.94 prior year.
- Full-year 2023 adjusted EPS $3.10 vs $3.36; Boston relaunch on track for mid-to-late Q2 2024.
- Signed definitive agreement to acquire Acclarent ENT business expected to close by Q2 2024.
- FY2024 guidance: revenue $1,603M-$1,618M (organic +4-5%), adjusted EPS $3.15-$3.25.
Key facts
Extracted from this filing and checked against the source text.
Earnings Releases
SEC 8-K Item 2.02
confidence 1.0
INTEGRA LIFESCIENCES HOLDINGS CORP reported full-year 2024 results: revenue $1,603 million to $1,618 million, EPS $3.15 to $3.25. Guidance initiated.
- Period
- full-year 2024
- Revenue
- $1,603 million to $1,618 million
- EPS
- $3.15 to $3.25
- Guidance
- initiated
- Result
- guidance update
Exact text from the filing
For the full-year 2024, the Company expects revenues to be in a range of $1,603 million to $1,618 million, representing reported growth of approximately 4.0% to 5.0% and organic growth in the range of 4.0% to 5.0%. Adjusted earnings per diluted share are expected to be between $3.15 and $3.25.
View on SEC.gov
Earnings Releases
SEC 8-K Item 2.02
confidence 1.0
INTEGRA LIFESCIENCES HOLDINGS CORP reported full-year 2023 results: revenue $1,541.6 million, net income $67.7 million, EPS $0.84.
- Period
- full-year 2023
- Revenue
- $1,541.6 million
- Net income
- $67.7 million
- EPS
- $0.84
- Result
- reported results
Exact text from the filing
Total reported revenues for the full-year 2023 were $1,541.6 million, a decrease of 1.0%, from the prior year. Organic sales for the full-year 2023 were flat compared to 2022. Revenue increas ed 5.5% on an organic basis excluding Boston. The Company reported GAAP net income of $67.7 million, or $0.84 per diluted share, for the full-year 2023, compared to GAAP net income of $180.6 million, or $2.16 per diluted share in 2022. Adjusted EBITDA for the full-year 2023 was $369.7 million, a decrease of $41.6 million versus the prior year. Full year EBITDA margins were 24.0% a decrease of 240 basis points from the prior year. Adjusted net income for the full-year 2023 was $247.8 million, or $3.10 per diluted share, compared to $280.9 million, or $3.36 per diluted share.
View on SEC.gov
Earnings Releases
SEC 8-K Item 2.02
confidence 1.0
INTEGRA LIFESCIENCES HOLDINGS CORP reported fourth quarter 2023 results: revenue 397.0 million, net income $19.8 million, EPS $0.25.
- Period
- fourth quarter 2023
- Revenue
- 397.0 million
- Net income
- $19.8 million
- EPS
- $0.25
- Result
- reported results
Exact text from the filing
Total reported revenues for the fourth quarter were 397.0 million, a decrease of 0.2% from the fourth quarter of 2022. Fourth quarter organic revenues were down 1.2% compared to the prior year. Revenue increased 3.6% on an organic basis excluding Boston. The Company reported GAAP net income of $19.8 million, or $0.25 per diluted share, in the fourth quarter of 2023, compared to GAAP net income of $52.9 million, or $0.63 per diluted share, in the prior year. Adjusted EBITDA for the fourth quarter of 2023 was $100.5 million, compared to $109.7 million in the fourth quarter of the prior year. As a percentage of revenue, adjusted EBITDA was 25.3%, a decrease of 230 basis points from the prior year period. Adjusted net income for the fourth quarter of 2023 was $69.1 million, or $0.89 per diluted share, compared to adjusted net income of $78.8 million, or $0.94 per diluted share, in the fourth quarter of 2022.
View on SEC.gov
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice.
See methodology for how this pipeline works.